Sahar Abdul Hameed Ali
Supervisor Name: Dr. Shatha Abdul Wadood
Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children; it represent about 75 % of all leukemia types in children of less than 15 years age, with the peak incidence age between (2-5) years age. In Iraq, the incidence of acute lymphoblastic leukemia represents 5 to 6 child patients per 100,000 of children. ALL can be treated by blood transfusion, chemotherapy, cranial irradiation, steroids, and bone marrow or stem cells transplantation. The chemotherapeutic agents used in the treatment of ALL may cause many adverse effects on the blood components, liver, pancreas, gastrointestinal tract, central nervous system, allergic reactions, and some other complications. Growth retardation and malnutrition were considered as the main adverse effects in children with ALL besides cardio-toxicity, neurotoxicity and early mortality. This research aimed to study the effect of chemotherapy on white blood cells count (WBC) in ALL patients. Methods: This study included 25 leukemic patients under chemotherapy from the Central Educational Hospital for Children in Baghdad city. Blood samples were drawn from patients before and after chemotherapy (Daunorubicin 25mg/m2 ). WBC and Lymphocytes (LYM) were measured. Descriptive data were expressed as mean (±) SD. Baseline and outcome variables were compared using an independent student's t-test, p value of less than 0.05 was used to express significant statistical difference. Results: WBC mean level showed significant decrease (5.463±2.736mm/hr), after chemotherapy in comparison with that before chemotherapy (57.892±54.725mm/hr) (p=0.000). LYM showed significant decrease (p=0.002) after chemotherapy (2.083±1.476 mm/hr) in comparison with that before chemotherapy (26.506±37.453mm/hr). Conclusions: reduced WBC levels in leukemic patients after chemotherapy increase the risk for infection and antibiotics is recommended to treat infection.